Cardiol Therapeutics Inc reports results for the quarter - Earnings Summary

• Cardiol Therapeutics Inc CRDL.TO reported a quarterly adjusted loss of 18 cents​​ per share for the quarter , lower than the same quarter last year, when the company reported EPS of -9 cents. The mean expectation of three analysts for the quarter was for a loss of 11 cents per share. Wall Street expected results to range from -12 cents to -11 cents per share.

• Reported revenue was zero​; analysts expected zero.

• Cardiol Therapeutics Inc's reported EPS for the quarter was a loss of 18 cents​.

• The company reported a quarterly loss of C$12.73 million.

• Cardiol Therapeutics Inc shares had fallen by 6.1% this quarter and gained 120.6% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 8.1% in the last three months.​

• In the last 30 days, there have been no negative revisions of earnings estimates

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

• The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Cardiol Therapeutics Inc is 9.00

This summary was machine generated from LSEG data November 15 at 02:02 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)